Treatment of liver damage should be focused at different stages of liver disease development, for example, the early stage of the disease is based on allopathic and symptomatic treatment, while the advanced stage of the disease may require consideration of anti-cancer treatment and liver transplantation. Basic treatment strategies include elimination of various causative factors, protection of liver function, replacement of liver function, comprehensive treatment, liver transplantation, etc. The action link of hepatoprotective drugs is in the symptomatic treatment phase, which acts against abnormal cell proliferation, increased matrix, inflammatory response, hepatocyte membrane damage, lipid metabolism disorders, energy metabolism disorders, and free radical damage present in the liver. The mechanisms of action of anti-inflammatory and hepatoprotective drugs include: anti-free radicals, antioxidants, repair of cell membranes and organelles, restoration of cellular functions, improvement of cellular metabolism, and promotion of detoxification functions. Therefore, hepatoprotective drugs can play an important role in a variety of liver disease areas. Viral hepatitis In the treatment of chronic hepatitis B, antiviral is the key, but the current antiviral therapy cannot solve all clinical problems, and the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China state that anti-inflammatory and hepatoprotective therapy is part of the comprehensive treatment. Hepatic inflammatory necrosis and its resulting liver fibrosis are the main pathological basis for disease progression, and if liver tissue inflammation can be effectively suppressed, it is possible to reduce hepatocyte destruction and slow down the development of fibrosis. Hepatoprotective and anti-inflammatory drugs can reduce the extent of damage to hepatocytes during viral clearance by the immune system and improve pre-existing and viral-resistant liver damage. Drug-induced liver injury First of all, the relevant drugs should be discontinued and specific antidotes (if any) should be given promptly; on the basis of strengthening supportive therapy, maintaining water and electrolyte balance, promoting hepatocyte regeneration and preventing complications, liver-protective anti-inflammatory, anti-yellowness and liver fibrosis prevention treatment can be carried out. After ALT, AST and GGT all return to normal, then slowly reduce the dosage and gradually stop the drug. Fatty liver disease Although further studies are needed to confirm whether hepatoprotective drugs reduce intrahepatic fat content, it has been found that hepatoprotective drugs may improve the ability of simple fatty liver to prevent “second strike” by repairing biofilm, antagonizing oxidative stress/lipid peroxidation, anti-inflammatory, anti-apoptotic and anti-fibrosis mechanisms, thus stopping the progression of chronic The treatment is designed to prevent the progression of liver disease and avoid the occurrence of cirrhosis, hepatocellular carcinoma and liver failure. It is indicated for: fatty liver with no improvement in imaging after six months of basic treatment, with steatohepatitis or liver fibrosis risk factors; NAFLD with persistent abnormal liver enzymes or liver biopsy confirmed inflammation and fibrosis (NASH); cryptogenic fatty liver with clinical or liver biopsy suggestive of chronic liver disease; prophylactic use for rapid weight loss and/or regular lipid-lowering drug therapy. Other liver damage In addition to the above diseases, liver-protective anti-inflammatory drugs are also indicated for alcoholic fatty liver, autoimmune hepatitis, in addition to: 1. When liver damage occurs in systemic diseases induced by multiple etiologies, the primary disease should be treated first, while anti-inflammatory and liver-protective treatment can be administered; 2. For industrial pollution, occupational diseases, environmental toxic liver diseases that still have abnormal liver function after treatment for the etiology, they should be supplemented with appropriate For those who have elevated liver enzymes for unknown reasons, effective anti-inflammatory and liver-protective treatment can be used at the right time and in the right amount without affecting the examination and diagnosis. Preventive use of hepatoprotective drugs In the following special circumstances, preventive use of hepatoprotective drugs can also be used to reduce liver damage, such as 1, anti-tumor chemotherapy, especially when using large doses of chemotherapy drugs; 2, anti-tuberculosis chemotherapy, especially when using multiple species in combination; 3, the use of anti-rejection drugs after organ transplantation; 4, long-term use of hypoglycemic drugs; 5, long-term use of drugs for the treatment of hyperthyroidism. Although hepatoprotective and anti-inflammatory drugs can “protect the liver”, they should not be applied arbitrarily, and some precautions should be taken when applying anti-inflammatory and hepatoprotective treatment: it is not advisable to apply multiple anti-inflammatory and hepatoprotective drugs at the same time, so as not to increase the burden on the liver; master the performance of various anti-inflammatory and hepatoprotective drugs and precautions for their use, and use them rationally; during the period of medication Regularly observe the patient’s symptoms, signs and changes in liver function; do not stop the medication suddenly if it is effective, but gradually reduce the dosage and stop it slowly according to the condition to avoid recurrence of the disease.